Bicara Therapeutics (NASDAQ:BCAX) said its pivotal study of FICERA in a form of advanced head and neck cancer has reached sufficient enrollment to support a planned top-line interim analysis in mid-2027.
The company also confirmed plans for an interim overall survival analysis in the FORTIFI-HN01 trial, although it did not say whether that analysis would occur at the same time as the anticipated top-line readout. Interim Chief Executive Officer Ryan Cohlhepp said Bicara would provide more detail on timing and scope as its plans are refined.
The update comes as Bicara prepares for potential competition in first-line recurrent or metastatic HPV-negative head and neck cancer. Cohlhepp said the company is seeking both speed to market and a regulatory submission that supports a competitive product label.
Trial Size and Survival Analysis
FORTIFI-HN01 is a blinded study comparing FICERA, also known as ficerafusp alfa, plus pembrolizumab with pembrolizumab alone. Cohlhepp said the trial was designed for approximately 650 patients, all with HPV-negative disease, and that Bicara does not need to increase its size to accommodate an interim survival analysis.
Chief Medical Officer Bill Schelman said Bicara expects to report response characteristics at the interim readout, including measures of response depth and durability. The company did not specify the number of survival events or the statistical power expected for the interim survival analysis.
Cohlhepp said a three- to four-month overall survival improvement over the historical standard of care would have been considered meaningful, while adding that expectations for competitiveness are evolving. He said it was difficult to speculate without more information from other studies.
FICERA has received U.S. Food and Drug Administration Breakthrough Therapy designation for HPV-negative head and neck cancer. Cohlhepp said Bicara has an ongoing dialogue with the FDA but declined to provide specifics about its regulatory strategy or the timing of future interactions.
Earlier Data and Competition
Schelman reviewed previously presented Phase 1b results for FICERA plus pembrolizumab, cautioning that the pivotal study remains blinded and ongoing. At the 1,500-milligram weekly dose, the combination produced a confirmed objective response rate of 54% and a complete response rate of 25%, with a median follow-up of three years.
Median response duration was nearly 22 months, median progression-free survival was 9.9 months and median overall survival was just over 21 months, Schelman said. About one-third of patients were alive at three years. The company said all patients in that dataset had HPV-negative disease.
Bicara executives said HPV status is important when interpreting results because outcomes can differ between HPV-positive and HPV-negative patients. Cohlhepp said more information is needed about recently announced results from a peer, including outcomes by HPV status and the maturity of survival data.
Asked about competition from petosemtamab, Cohlhepp said Bicara continues to expect less than a year between the potential approvals of the two therapies. He also said the company now considers it more likely that both initial labels could include overall survival data, while acknowledging uncertainty about regulators’ decisions and the maturity of the competing data.
Chief Commercial Officer Chris Sarchi said Bicara recognizes the advantages of being first to market but is focused on a differentiated submission and clinical profile. The company is also evaluating less frequent FICERA dosing in the FORTIFI-FLEX study and expects those data before its first potential approval, Cohlhepp said.
Colorectal Cancer Data and Quarterly Spending
Bicara plans to present data in January 2027 from a Phase 1b expansion study of FICERA, both alone and with pembrolizumab, in patients with later-line microsatellite-stable, RAS/BRAF wild-type metastatic colorectal cancer. Cohlhepp said the company is looking for an efficacy signal and a safety profile that could support combinations in earlier lines of treatment.
For the third quarter of 2026, research and development expenses rose to $56.5 million from $33 million a year earlier, reflecting clinical trial and personnel costs. General and administrative expenses increased to $19.2 million from $7.7 million, primarily because of additional personnel costs and professional fees as the company expanded.
Chief Financial Officer Jenn Larson said Bicara ended the quarter with approximately $442.3 million in cash, equivalents and marketable securities, which it expects to fund operations into the first half of 2029. She said operating expenses through year-end are expected to remain consistent with the most recent quarter.
About Bicara Therapeutics (NASDAQ:BCAX)
Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.
Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.
